Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Amortizatization of Intangibles (2022 - 2025)

Historic Amortizatization of Intangibles for Rani Therapeutics Holdings (RANI) over the last 4 years, with Q3 2025 value amounting to $472000.0.

  • Rani Therapeutics Holdings' Amortizatization of Intangibles fell 3276.35% to $472000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 595.44%. This contributed to the annual value of $1.8 million for FY2024, which is 2189.12% down from last year.
  • As of Q3 2025, Rani Therapeutics Holdings' Amortizatization of Intangibles stood at $472000.0, which was down 3276.35% from $478000.0 recorded in Q2 2025.
  • Rani Therapeutics Holdings' Amortizatization of Intangibles' 5-year high stood at $702000.0 during Q3 2024, with a 5-year trough of $157000.0 in Q1 2022.
  • Its 4-year average for Amortizatization of Intangibles is $426866.7, with a median of $472000.0 in 2025.
  • Per our database at Business Quant, Rani Therapeutics Holdings' Amortizatization of Intangibles skyrocketed by 34522.29% in 2023 and then crashed by 5359.12% in 2024.
  • Rani Therapeutics Holdings' Amortizatization of Intangibles (Quarter) stood at $323000.0 in 2022, then skyrocketed by 43.96% to $465000.0 in 2023, then increased by 2.58% to $477000.0 in 2024, then dropped by 1.05% to $472000.0 in 2025.
  • Its Amortizatization of Intangibles stands at $472000.0 for Q3 2025, versus $478000.0 for Q2 2025 and $477000.0 for Q1 2025.